ADAP News and Press, Adaptimmune Therapeutics plc From 09/07/21

FinancialBuzz.com’s latest The Buzz Show: Featuring Our Corporate News Recap on “Adaptimmune Therapeutics plc on the Rise After Entering into a Strategic Collaboration with Genentech” Adaptimmune Therapeutics (NASDAQ: ADAP) plc climbed over 23%...

Shares of the clinical-stage biotech Adaptimmune Therapeutics (NASDAQ: ADAP) popped by as much as 25% in premarket trading Tuesday morning. The cancer specialist's stock is on the move this morning in response to a licensing and collaboration agreement with Roche 's (OTC: RHHB...

- Combining both companies’ cell therapy leadership and expertise, the collaboration covers the research and development of “off-the-shelf” cell therapies for up to five shared cancer targets and the development of a novel allogeneic personalized cell therapy platform -...

- One complete response, and a disease control rate of 64% with stable disease for ≥16 weeks in two patients, as of the data cutoff - - Data presented today at the International Liver Cancer Association meeting at 12:25 p.m. CET - PHILADELPHIA and OXFORDSHIRE, United Kingdom,...

You can read full article here. For further details see: Wall Street Breakfast: The Week Ahead (Podcast)

Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha, iTunes, Stitcher and Spotify. Economic reports in the week ahead The latest trading week of the slower season could be an active one. Economic reports out include updates on pending hom...

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha, Apple Po...

Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. Mond...

Adaptimmune Therapeutics (NASDAQ: ADAP) , a clinical-stage biotech, saw its shares spike by as much as 10% in early morning trading Monday. Although the stock has cooled off somewhat in afternoon trading, its shares were still up by a healthy 8% as of 12:52 p.m. EDT Monday. Adap...

Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. Mond...